{"meta":{"query_hash":"e79e9d150f2b","filters":{"venue":"Bali Dermatology and Venereology Journal"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/e79e9d150f2b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Bali+Dermatology+and+Venereology+Journal"},"results":[{"id":"W4249533637","doi":"10.15562/bdv.v3i2.38","title":"Focus on the dabrafenib, vemurafenib, and trametinib in clinical outcome of melanoma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Bali Dermatology and Venereology Journal","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trametinib; Dabrafenib; Vemurafenib; Medicine; Oncology; Internal medicine; Melanoma; MEK inhibitor; Targeted therapy; Randomized controlled trial; Meta-analysis; Cancer; Cancer research; Metastatic melanoma; MAPK/ERK pathway","score_opus":0.10863957499082004,"score_gpt":0.3745808384374596,"score_spread":0.26594126344663954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249533637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019900831,0.9967186,0.00024999687,0.00020406446,0.00008430424,0.00015583976,0.00041376485,0.000012334944,0.00017097639],"genre_scores_gemma":[0.10560778,0.88982743,0.0012434149,0.0010216996,0.00021759798,0.0009206916,0.00081541995,0.000029662675,0.0003162477],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9892196,0.004658224,0.0033507382,0.001086374,0.0012945601,0.00039049238],"domain_scores_gemma":[0.976824,0.017078053,0.003487553,0.00049392885,0.0018186517,0.00029774473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01575955,0.0030187268,0.019431654,0.008432922,0.0006782024,0.0035990176,0.002214914,0.0021953615,0.0045168563],"category_scores_gemma":[0.03489322,0.0011745726,0.040180527,0.009596531,0.0007122267,0.0020930753,0.0016945138,0.0018024851,0.00032355494],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009205907,0.000020303605,0.003389616,0.5946163,0.38998246,0.00012828346,0.00008856005,0.00034222464,0.00015150152,0.0001732804,0.00067808025,0.009508756],"study_design_scores_gemma":[0.0002822956,0.00012398101,0.0032811777,0.05478493,0.93884456,0.0001195072,0.00006290372,0.00012447563,0.000084867046,0.00019360859,0.0020761597,0.000021470807],"about_ca_topic_score_codex":0.009239283,"about_ca_topic_score_gemma":0.022200624,"teacher_disagreement_score":0.019431654,"about_ca_system_score_codex":0.0032813733,"about_ca_system_score_gemma":0.0056493985,"threshold_uncertainty_score":0.08334541},"labels":[],"label_agreement":null}]}